In Autumn 2020, DOAJ will be relaunching with a new website with updated functionality, improved search, and a simplified application form. More information is available on our blog. Our API is also changing.

Hide this message

The Difference in the Changes of Indoxyl Sulfate after Catheter Ablation among Atrial Fibrillation Patients with and without Kidney Dysfunction

Scientific Reports. 2020;10(1):1-8 DOI 10.1038/s41598-020-57421-z

 

Journal Homepage

Journal Title: Scientific Reports

ISSN: 2045-2322 (Online)

Publisher: Nature Publishing Group

LCC Subject Category: Medicine | Science

Country of publisher: United Kingdom

Language of fulltext: English

Full-text formats available: PDF, HTML

 

AUTHORS


Hideki Koike (Department of Cardiovascular Medicine, Toho University Faculty of Medicine)

Toshisuke Morita (Department of Laboratory Medicine, Toho University Faculty of Medicine)

Junko Tatebe (Department of Laboratory Medicine, Toho University Faculty of Medicine)

Ippei Watanabe (Department of Cardiovascular Medicine, Toho University Faculty of Medicine)

Masaya Shinohara (Department of Cardiovascular Medicine, Toho University Faculty of Medicine)

Toshio Kinoshita (Department of Cardiovascular Medicine, Toho University Faculty of Medicine)

Hitomi Yuzawa (Department of Cardiovascular Medicine, Toho University Faculty of Medicine)

Takeya Suzuki (Department of Cardiovascular Medicine, Toho University Faculty of Medicine)

Tadashi Fujino (Department of Cardiovascular Medicine, Toho University Faculty of Medicine)

Takanori Ikeda (Department of Cardiovascular Medicine, Toho University Faculty of Medicine)

EDITORIAL INFORMATION

Blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 20 weeks

 

Abstract | Full Text

Abstract Indoxyl sulfate (IS), a protein-bound uremic toxin, induces chronic kidney disease (CKD) and atrial fibrillation (AF). Catheter ablation (CA) of AF improves the renal function. However, the transition of uremic toxins is unclear. This study aimed to investigate the transition of the serum IS level in AF patients with and without CKD after CA. A total of 138 consecutive AF patients who underwent CA and maintained sinus rhythm were prospectively enrolled (paroxysmal AF 67.4%). The patients were divided into 4 groups (non-CKD/low-IS:68, non-CKD/high-IS:28, CKD/low-IS:13, and CKD/high-IS:29). The plasma IS levels and estimated glomerular filtration rate (eGFR) were determined before and 1-year after CA. CKD was defined as CKD stage III and a high-IS according to the mean IS (IS ≥ 1.1 μg/ml). CA significantly improved the eGFR in CKD patients (p < 0.001). The serum IS level in the non-CKD/high-IS group was significantly decreased (from 1.7 ± 0.7 to 1.1 ± 0.6 μg/ml, p < 0.001). However, the serum IS level in the CKD/high-IS group did not improve (from 1.9 ± 0.9 to 1.7 ± 0.7 μg/ml, p = 0.22). The change in the IS in the CKD patients significantly differed from that in those without CKD. In the CKD patients, CA did not significantly decrease the IS, a risk factor of CKD, regardless of an improved eGFR.